Clinical Study of Combination Therapy for Angina of Coronary Heart Disease With Aspirin and Salvianolate Injection
Primary Purpose
Angina
Status
Unknown status
Phase
Phase 4
Locations
China
Study Type
Interventional
Intervention
Salvianolate injection
Aspirin
Sponsored by
About this trial
This is an interventional treatment trial for Angina
Eligibility Criteria
Inclusion Criteria:
- Patient age 35-75 years old
- Grade II diagnostic criteria for chronic stable angina pectoris
- Diagnostic criteria of blood stasis type
- Signed informed consent
Exclusion Criteria:
- Drug allergy to the test
- There is a family or personal history of hemorrhagic disease
- Platelet count < 100 * nine times square 10/L or > 450 *nine times square 10/L
- Hemoglobin < 90g/L
- ALT, AST higher than the upper limit of 2 times, BUN, Cr higher than the upper limit
- Drugs such as the use of clopidogrel, clopidogrel, Hua Falin or heparin in the last 2 weeks to take blood circulation drugs or other antiplatelet, anticoagulant or non steroidal anti-inflammatory drugs
- Heart failure three degrees, two degrees in patients with heart failure
- A history of trauma or surgery in the past 2 weeks
- Combined coronary heart disease myocardial infarction and cerebral blood vessels, liver, kidney, hematopoietic system severe primary disease, malignant tumor, mental disease patients, as well as hyperthyroidism, cervical spondylosis, stomach and esophageal reflux and other patients with chest pain
- Organ transplantation, AIDS, long-term use of immunosuppressive agents and other immune deficiency
- Pregnant or lactating women
- Other clinical trial participants who are taking part in the evaluation of the results of this study
Sites / Locations
- Xiyuan Hospital of China Academy of Chinese Medical Sciences
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Other
Active Comparator
Experimental
Arm Label
Salvianolate injection group
Aspirin group
Salvianolate injection and aspirin group
Arm Description
Salvianolate injection,intravenously infusion,0.2g/time,once a day;other routine treatment according to the condition of the disease
Aspirin,oral administration method,0.1g/time,once a day;other routine treatment according to the condition of the disease
Salvianolate injection,intravenously infusion,0.2g/time,once a day;aspirin,oral administration method,0.1g/time,once a day;other routine treatment according to the condition of the disease
Outcomes
Primary Outcome Measures
Change of thromboela-stogram(R time,K time,α angle,MA、CI、TPI)
Thromboela-stogram(TEG) Is a reflection of the dynamic changes in blood coagulation (including the formation rate of fibrin, the dissolution of the state and the consistency of the solid, elastic degree) of the index: R time is the latency of the first fibrin plaque formation. K time is to assess the rate at which blood clots reach a certain level. The alpha angle is similar to the K time, but is more comprehensive than the K time, and is not affected by the low coagulation state. MA reflects the maximum amplitude of blood clots. CI is an integrated coagulation index.TPI is the index of platelet kinetics
Secondary Outcome Measures
Change of symptom score of the Seattle Angina Questionnaiire(SAQ)
SAQ includes 5 dimensions: the degree of physical activity limitation, the stable state of angina pectoris, the frequency of angina attack, the degree of treatment satisfaction, and the recognition of the disease
Change of ECG abnormalities
ECG is the most common method of detection of myocardial ischemia and the diagnosis of angina pectoris
Change of score of Traditional Chinese Medicine(TCM) symptom curative effect rating scale
It includes the description of scores of symptoms, signs of tongue and pulse related to blood stasis syndrome of diagnosis of traditional Chinese medicine
Change of platelet aggregation measured by light transmittance aggregometry(LTA)
The method is widely recognized, and is even considered a gold standard
Change of serum lipids(TC、TG、HDL-C、LDL-C)
Hyperlipidemia is one of the causes of angina. The measurement units of four indicators(TC、TG、HDL-C、LDL-C)are "mmol/L"
Change of fasting blood glucose
It is one of the causes of angina(especially for patients with diabetes).The measurement unit is "mmol/L"
The blood concentration of magnesium lithospermate B
Population pharmacokinetics test is in order to study the relationship between the population pharmacokinetics and clinical outcome. Magnesium lithospermate B is the main effective components of Salvianolate injection.The detection of the blood concentration of magnesium lithospermate B from both salvianolate injection group and salvianolate injection and aspirin group is necessary.
The blood concentration of salicylic acid
Population pharmacokinetics test is in order to study the relationship between the population pharmacokinetics and clinical outcome. Salicylic acid is a kind of metabolite of aspirin. The detection of the blood concentration of salicylic acid from both aspirin group and salvianolate injection and aspirin group is necessary.
Full Information
NCT ID
NCT02694848
First Posted
February 14, 2016
Last Updated
February 24, 2016
Sponsor
China Academy of Chinese Medical Sciences
Collaborators
Xiyuan Hospital of China Academy of Chinese Medical Sciences, Guang'anmen Hospital of China Academy of Chinese Medical Sciences, General Hospital of Beijing PLA Military Region, Guangdong Provincial Hospital of Traditional Chinese Medicine
1. Study Identification
Unique Protocol Identification Number
NCT02694848
Brief Title
Clinical Study of Combination Therapy for Angina of Coronary Heart Disease With Aspirin and Salvianolate Injection
Official Title
Clinical Study of Combination Therapy for Angina of Coronary Heart Disease With Aspirin and Salvianolate Injection Based on Population Pharmacokinetics and Therapeutic Effect:A Randomized, Controlled Trial
Study Type
Interventional
2. Study Status
Record Verification Date
February 2016
Overall Recruitment Status
Unknown status
Study Start Date
February 2016 (undefined)
Primary Completion Date
December 2016 (Anticipated)
Study Completion Date
March 2017 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
China Academy of Chinese Medical Sciences
Collaborators
Xiyuan Hospital of China Academy of Chinese Medical Sciences, Guang'anmen Hospital of China Academy of Chinese Medical Sciences, General Hospital of Beijing PLA Military Region, Guangdong Provincial Hospital of Traditional Chinese Medicine
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
To evaluate the therapeutic evaluation of combination therapy with aspirin and salvianolate injection based on the population pharmacokinetics and TEG.A prospective, multicenter, randomized, controlled clinical trial is used.A total of 120 patients will be recruited and will be divided into three groups,respectively salvianolate injection group,aspirin group and salvianolate injection and aspirin group,and the course of treatment is 10 days.
Detailed Description
Effectiveness evaluation:Primary Outcome Measure:Change of TEG(R time, K time, α angle, MA,CI,TPI).Secondary Outcome Measures: Change of symptom score of the Seattle Angina Questionnaiire(SAQ).Change of ECG abnormalities.Change of score of traditional Chinese medicine(TCM) symptom curative effect rating scale. Change of platelet aggregation measured by light transmittance aggregometry(LTA).Change of serum lipids(TC、TG、HDL-C、LDL-C).Change of fasting blood glucose.Population pharmacokinetics test(the detection of the blood concentration of magnesium lithospermate B and salicylic acid).
Safety evaluation:Change of PT,APTT,TT,FIB.Adverse events.Change of basic life sign.Gastrointestinal symptoms.Change of stool routine.Change of routine blood test.Change of urine routine.Change of liver function.Change of renal function.Change of fecal occult blood.
Number of participants:120 participants will be divided into three groups, the salvianolate group (n=40), the aspirin group(n=40) and the combination therapy group of salvianolate injection and aspirin(n=40).
Interventions:salvianolate injection group: salvianolate injection, intravenously infusion,0.2g/time, once a day; other routine treatment according to the condition of the disease.Aspirin group: aspirin, oral administration method,0.1g/time, once a day; other routine treatment according to the condition of the disease.Salvianolate injection and aspirin group: salvianolate injection, intravenously infusion,0.2g/time, once a day; aspirin, oral administration method,0.1g/time, once a day; other routine treatment according to the condition of the disease.
Course of treatment:10 days.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Angina
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
Investigator
Allocation
Randomized
Enrollment
120 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Salvianolate injection group
Arm Type
Other
Arm Description
Salvianolate injection,intravenously infusion,0.2g/time,once a day;other routine treatment according to the condition of the disease
Arm Title
Aspirin group
Arm Type
Active Comparator
Arm Description
Aspirin,oral administration method,0.1g/time,once a day;other routine treatment according to the condition of the disease
Arm Title
Salvianolate injection and aspirin group
Arm Type
Experimental
Arm Description
Salvianolate injection,intravenously infusion,0.2g/time,once a day;aspirin,oral administration method,0.1g/time,once a day;other routine treatment according to the condition of the disease
Intervention Type
Drug
Intervention Name(s)
Salvianolate injection
Intervention Description
Traditional Chinese medicine injection,a kind of innovative drugs developed by Shanghai institute of materia medica, Chinese academy of sciences after 13 years of research and development.the content of magnesium acetate was 80%, and the other 20% were magnesium acetate.It has the function of promoting blood circulation,removing blood stasis and blood stasis,and is used for treating coronary heart disease with stable angina pectoris.
Intervention Type
Drug
Intervention Name(s)
Aspirin
Intervention Description
Molecular chemical formula: C9H8O4,molecular structure type: CH3COOC6H4COOH. It has the role of anti thrombosis In vivo, and it can inhibit the release of the platelet reaction, inhibit platelet aggregation, which is related to the reduction of TXA2 generation. Clinically itused to prevent the onset of cardiovascular and cerebrovascular diseases.
Primary Outcome Measure Information:
Title
Change of thromboela-stogram(R time,K time,α angle,MA、CI、TPI)
Description
Thromboela-stogram(TEG) Is a reflection of the dynamic changes in blood coagulation (including the formation rate of fibrin, the dissolution of the state and the consistency of the solid, elastic degree) of the index: R time is the latency of the first fibrin plaque formation. K time is to assess the rate at which blood clots reach a certain level. The alpha angle is similar to the K time, but is more comprehensive than the K time, and is not affected by the low coagulation state. MA reflects the maximum amplitude of blood clots. CI is an integrated coagulation index.TPI is the index of platelet kinetics
Time Frame
Change from base line on the tenth day
Secondary Outcome Measure Information:
Title
Change of symptom score of the Seattle Angina Questionnaiire(SAQ)
Description
SAQ includes 5 dimensions: the degree of physical activity limitation, the stable state of angina pectoris, the frequency of angina attack, the degree of treatment satisfaction, and the recognition of the disease
Time Frame
Change from base line on the tenth day
Title
Change of ECG abnormalities
Description
ECG is the most common method of detection of myocardial ischemia and the diagnosis of angina pectoris
Time Frame
Change from base line on the tenth day
Title
Change of score of Traditional Chinese Medicine(TCM) symptom curative effect rating scale
Description
It includes the description of scores of symptoms, signs of tongue and pulse related to blood stasis syndrome of diagnosis of traditional Chinese medicine
Time Frame
Change from base line on the tenth day
Title
Change of platelet aggregation measured by light transmittance aggregometry(LTA)
Description
The method is widely recognized, and is even considered a gold standard
Time Frame
Change from base line on the tenth day
Title
Change of serum lipids(TC、TG、HDL-C、LDL-C)
Description
Hyperlipidemia is one of the causes of angina. The measurement units of four indicators(TC、TG、HDL-C、LDL-C)are "mmol/L"
Time Frame
Change from base line on the tenth day
Title
Change of fasting blood glucose
Description
It is one of the causes of angina(especially for patients with diabetes).The measurement unit is "mmol/L"
Time Frame
Change from base line on the tenth day
Title
The blood concentration of magnesium lithospermate B
Description
Population pharmacokinetics test is in order to study the relationship between the population pharmacokinetics and clinical outcome. Magnesium lithospermate B is the main effective components of Salvianolate injection.The detection of the blood concentration of magnesium lithospermate B from both salvianolate injection group and salvianolate injection and aspirin group is necessary.
Time Frame
At the discretional two time points from the time point after treatment(0h,0.25h(15min),0.5h,0.75h(45min),1h,1.17h(70min),1.33h(80min),1.67h(100min),2h,2.5h,3h,4h,5h,7h,9h,13h,25h)
Title
The blood concentration of salicylic acid
Description
Population pharmacokinetics test is in order to study the relationship between the population pharmacokinetics and clinical outcome. Salicylic acid is a kind of metabolite of aspirin. The detection of the blood concentration of salicylic acid from both aspirin group and salvianolate injection and aspirin group is necessary.
Time Frame
At the discretional two time points from the time point after treatment(0h,0.5h,1h,1.5h,2h,2.5h,3h,4h,5h,6h,8h,9h,10h,12h)
Other Pre-specified Outcome Measures:
Title
Change of PT
Description
An index to reflect the status of the extrinsic coagulation system
Time Frame
Change from base line on the tenth day
Title
Adverse events
Time Frame
Change from base line on the tenth day
Title
Change of basic life sign
Description
In the medical care system, body temperature, blood pressure and pulse are the most important and basic three physiological parameters of the vital signs
Time Frame
Change from base line on the tenth day
Title
Gastrointestinal symptoms
Time Frame
Change from base line on the tenth day
Title
Change of stool routine
Description
The stool routine includes stool properties, lipid droplets, and white blood cell count
Time Frame
Change from base line on the tenth day
Title
Change of routine blood test
Description
The routine blood test includes white blood cell count, neutral cell ratio, lymphocyte ratio, single nuclear cell ratio, red blood cell count, hemoglobin, platelet count
Time Frame
Change from base line on the tenth day
Title
Change of urine routine
Description
The urine routine includes white blood cell count, red blood cell count,urine protein,urine sugar
Time Frame
Change from base line on the tenth day
Title
Change of liver function
Description
The liver function includes glutamic-pyruvic transaminase,glutamic-oxalacetic transaminase
Time Frame
Change from base line on the tenth day
Title
Change of renal function
Description
The renal function includes creatinine,usea nitrogen
Time Frame
Change from base line on the tenth day
Title
Change of fecal occult blood
Description
In order to monitor the safety of the digestive tract (if there is bleeding)
Time Frame
Change from base line on the tenth day
Title
Change of APTT
Description
An index to reflect the status of endogenous coagulation system
Time Frame
Change from base line on the tenth day
Title
Change of TT
Description
An index to reflect the time consuming from the fibrinogen into fibrin
Time Frame
Change from base line on the tenth day
Title
Change of FIB
Description
An index to reflect the content of fibrinogen
Time Frame
Change from base line on the tenth day
10. Eligibility
Sex
All
Minimum Age & Unit of Time
35 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Patient age 35-75 years old
Grade II diagnostic criteria for chronic stable angina pectoris
Diagnostic criteria of blood stasis type
Signed informed consent
Exclusion Criteria:
Drug allergy to the test
There is a family or personal history of hemorrhagic disease
Platelet count < 100 * nine times square 10/L or > 450 *nine times square 10/L
Hemoglobin < 90g/L
ALT, AST higher than the upper limit of 2 times, BUN, Cr higher than the upper limit
Drugs such as the use of clopidogrel, clopidogrel, Hua Falin or heparin in the last 2 weeks to take blood circulation drugs or other antiplatelet, anticoagulant or non steroidal anti-inflammatory drugs
Heart failure three degrees, two degrees in patients with heart failure
A history of trauma or surgery in the past 2 weeks
Combined coronary heart disease myocardial infarction and cerebral blood vessels, liver, kidney, hematopoietic system severe primary disease, malignant tumor, mental disease patients, as well as hyperthyroidism, cervical spondylosis, stomach and esophageal reflux and other patients with chest pain
Organ transplantation, AIDS, long-term use of immunosuppressive agents and other immune deficiency
Pregnant or lactating women
Other clinical trial participants who are taking part in the evaluation of the results of this study
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Lianxin Wang, doctor
Phone
86-13521781839
Email
wanglianxin_tcm@126.com
First Name & Middle Initial & Last Name or Official Title & Degree
Junjie Jiang, doctor
Phone
86-18910206360
Email
studentjiangjunjie@163.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Yanming Xie, Study Chair
Organizational Affiliation
Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences
Official's Role
Study Chair
Facility Information:
Facility Name
Xiyuan Hospital of China Academy of Chinese Medical Sciences
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100091
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Keji Chen, Academician
Phone
86-13521781839
Email
wlxing@126.com
First Name & Middle Initial & Last Name & Degree
Mei Xue, doctor
Phone
86-13581801296
Email
meiar@126.com
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
33360345
Citation
Lyu J, Xue M, Li J, Lyu W, Wen Z, Yao P, Li J, Zhang Y, Gong Y, Xie Y, Chen K, Wang L, Chai Y. Clinical effectiveness and safety of salvia miltiorrhiza depside salt combined with aspirin in patients with stable angina pectoris: A multicenter, pragmatic, randomized controlled trial. Phytomedicine. 2021 Jan;81:153419. doi: 10.1016/j.phymed.2020.153419. Epub 2020 Dec 10.
Results Reference
derived
Learn more about this trial
Clinical Study of Combination Therapy for Angina of Coronary Heart Disease With Aspirin and Salvianolate Injection
We'll reach out to this number within 24 hrs